Survivre à une mutation T315I

[cousineg]

Lorsqu'on est atteint par la mutation T315I, on a 80% de chance de
survivre si on est en phase chronique, 56% si on est en phase accélérée
et 32% si on est en phase blastique. Ces statistiques ont été prises sur une période de temps ( environ 18 mois après la détection de la mutation).
mais combien d'années, peut-on survivre avec une mutation T315I. Seul, l'avenir le dira.

Ces chiffres sont quand même encourageants et démontrent qu'il est
possible de survivre plus longtemps à une mutation T315I surtout si on est en phase chronique.

J'imagine que les pourcentages de survies vont s'améliorer avec les recherches sur la mutation T315I

http://bloodjournal.hematologylibrary.o ... type=HWCIT

[cousineg]

Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
Blood, 17 December 2009, Vol. 114, No. 26, pp. 5271-5278
http://bloodjournal.hematologylibrary.o ... type=HWCIT

[cousineg]

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I
Nikolai Velev, MD 1, Jorge Cortes, MD 1 *§, Richard Champlin, MD 2, Dan Jones, MD, PhD 3, Gabriela Rondon, MD 2,
Sergio Giralt, MD 2, Gautam Borthakur, MD 1, Hagop M. Kantarjian, MD 1, Marcos De Lima, MD 2
1Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
3Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Abstract
BACKGROUND:
Resistance to tyrosine kinase inhibitor (TKIs) therapy is associated with the development of kinase domain mutations. Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion Bcr-Abl (T315I) is insensitive to all currently available TKIs. The outcome in such patients after stem cell transplantation (SCT) is unknown.
METHODS:
Eight patients with TKI-resistant CML who had T315I mutations underwent 9 transplantations. At the time of SCT, 2 patients were in chronic phase, 3 patients were in accelerated phase; and 3 patients were in second chronic phase.
RESULTS:
The best responses after SCT were a complete molecular response (CMR) in 3 patients, a complete cytogenetic response (CCyR) in 4 patients, and a complete hematologic response (CHR) in 1 patient, and 1 patient had no response. The best outcome was for patients who underwent transplantation in chronic phase, and both of those patients remained alive and in complete molecular remission 14 months and 42 months after SCT. After a median follow-up of 13 months from SCT, 5 patients remained alive, including 3 patients in CMR, 1 patient in CCyR, and 1 patient in CHR.
CONCLUSIONS:
The current results indicated that SCT is an effective strategy for patients with CML who have the T315I mutation, particularly in earlier stages. Cancer 2010. © 2010 American Cancer Society.
Extrait de http://www3.interscience.wiley.com/jour ... 4/abstract

[cousineg]

Voir Le point sur la lutte contre la mutation T315I - Septembre 2009

[cousineg]

Voir les récents développements relatifs à la mutation T315I http://www.cmleukemia.com/mutation-t315i.html

[cousineg]

Voir L'omacetaxine, nouveau traitement pour la mutation T315I

[cousineg]

......
Bonne nouvelle! Nouvel inhibiteur pour traiter la mutation T315I
Voir Novel potent inhibitor (P2745 )of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines (included T315I)

Autre lien: Mutation T315I

......